

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ryozo NAGAI et al.

Group Art Unit : 1611

Appl. No. : 10/598,275

Examiner : Charlesworth RAE

I. A. Filed : February 24, 2005

Confirmation No. : 2170

For : MEDICINE CAPABLE OF INHIBITING ACTIVATION OF
TRANSCRIPTION FACTOR KLF5

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir :

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56 and 1.97-1.98, and further to the Information Disclosure Statement submitted March 28, 2007, Applicants hereby call to the Examiner's attention the following documents:

1. SHINDO et al., "Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotension II signaling and an essential regulator of cardiovascular remodeling" *Nature Medicine* Vol. 8, No. 8, pages 856-863, 2002; and
2. KOWASE et al., "Retinoic acid inhibits BTEB2 gene expression and its function in vascular smooth muscle cells: The potential role of BTEB2 in retinoic acid-mediated inhibition of neointimal formation after balloon injury" *Circulation* Vol. 102, No. 18, suppl., page II-247, 2000.

Applicants also direct the Examiner's attention to the attached Partial European Search Report issued in connection with EP 05 71 0637 in which the above-listed documents were cited. The relevance of the documents cited in the Partial European Search Report as ascertained with respect to the European claims by the European Examiner is set forth in the Partial European Search Report.


Copies of the KOWASE et al. document and the European Search Report are enclosed herewith for the Examiner's consideration. Applicants note that a copy of the SHINDO et al. document was previously provided in the Information Disclosure Statement of March 28, 2007. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the Form PTO-1449 with the next communication.

In accordance with 37 C.F.R. § 1.97(e), the undersigned hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application no more than three months prior to the filing of the Information Disclosure Statement. Of course, this statement does not apply to information that has previously been cited by Applicants or the Examiner in the present application as that information is already of record and no certification is necessary.

Applicants further note that this Information Disclosure Statement is being submitted after the filing of a Request for Continued Examination (RCE) on March 16, 2009. No fee is deemed necessary to ensure consideration of this statement. However, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully Submitted,
Ryozo NAGAI et al.



Bruce H. Bernstein
Reg. No. 29,027

September 21, 2009
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Arnold Turk
Reg. No. 33094